Akston Biosciences Corporation leverages its novel fusion protein platform to develop and manufacture new classes of biologics, including vaccines, ultra-long-acting insulins, and autoimmune disease therapies. Akston has partnered with Biolexis Private Limited of the Strides Group to manufacture and commercialize AKS-452 (branded as AmbiVax-CTM) in India and over 130 countries in Asia, Latin America, and Africa. It has also partnered Dechra Pharmaceuticals PLC (DPH) to commercialize once-a-week canine and feline insulin therapies. It was founded by the team that developed the world’s first clinical glucose-responsive insulin at SmartCells, Inc. (sold to Merck & Co.). Akston operates a GMP biologics manufacturing cleanroom facility and research laboratory at its Beverly, Mass. location.